文献速递角膜与眼表疾病

人血小板裂解液治疗暴露性角膜病变:活体共聚焦显微镜与前节OCT研究

Human Platelet Lysate Treatment for Exposure Keratopathy: An In Vivo Confocal Microscopy and Anterior Segment OCT Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

在兔暴露性角膜病变模型中,局部应用人血小板裂解液(HPL)、胎牛血清(FBS)、无防腐剂人工泪液(PFAT)或皮质类固醇,观察到HPL和FBS组角膜厚度恢复更有效,HPL、FBS和皮质类固醇组炎症细胞浸润显著减少,HPL组Ki-67阳性细胞更多。

要点

  • HPL和FBS治疗组角膜变薄恢复更有效,包括上皮、基质和总角膜厚度改善。
  • HPL、FBS和皮质类固醇组较PFAT组中央角膜、周边角膜和结膜炎症细胞浸润显著减少。
  • HPL组较PFAT组和皮质类固醇组Ki-67阳性细胞更多。

核心结论

  • HPL治疗有效减轻炎症、促进角膜厚度恢复并在脱水后诱导细胞增殖,显示其作为暴露性角膜病变治疗方法的潜力。

研究设计与样本

  • 在新西兰白化兔中通过睁眼4小时再闭眼4小时诱导短期暴露性角膜病变,期间给予HPL、FBS或无防腐剂人工泪液每15分钟一次,皮质类固醇每1小时一次。
  • 使用前节OCT和荧光素染色评估角膜厚度变化和上皮缺损,活体共聚焦显微镜评估炎症细胞浸润,免疫组化确认CD8+ T细胞、中性粒细胞、巨噬细胞和细胞增殖标记Ki67。

主要发现

  • 治疗完成后,四组间荧光素染色未见显著差异。
  • 前节OCT显示HPL和FBS治疗组角膜变薄恢复更有效,包括上皮、基质和总角膜厚度改善。
  • 活体共聚焦显微镜显示HPL、FBS和皮质类固醇组较PFAT组在中央角膜、周边角膜和结膜的炎症细胞浸润显著减少。
  • 免疫组化对CD8+ T细胞、中性粒细胞和巨噬细胞显示相似结果。
  • HPL治疗组较PFAT组和皮质类固醇组Ki-67阳性细胞更多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the effects of topical human platelet lysate (HPL) on exposure keratopathy (EK) in a rabbit model, with a focus on its anti-inflammatory and anti-dehydration properties on the cornea. METHODS: Short-term exposure keratopathy was induced in New Zealand albino rabbits by keeping the eyelids open for four hours, followed by eyelid closure for another four hours, during which the treatment was applied. HPL, fetal bovine serum (FBS), or preservative-free artificial tears (PFAT) were administered every 15 minutes, and corticosteroid was applied every one hour during the treatment period. Corneal thickness changes and epithelial defects were assessed using anterior segment optical coherence tomography (AS-OCT) and fluorescein staining. In vivo confocal microscopy (IVCM) was used to evaluate inflammatory cell infiltration, whereas immunohistochemistry (IHC) was performed to confirm the presence of CD8+ T cells, neutrophils, and macrophages and the cell proliferation marker Ki67. RESULTS: After completing the treatment, no significant difference in fluorescein staining was observed among the four groups. However, AS-OCT revealed more effective recovery of corneal thinning in the HPL- and FBS-treated groups, including improvements in epithelial, stromal, and total corneal thickness. IVCM revealed significantly reduced infiltration of inflammatory cells in the HPL-, FBS-, and corticosteroid-treated groups compared to the PFAT-treated group across the central cornea, peripheral cornea, and conjunctiva. IHC for CD8+ T cells, neutrophils, and macrophages showed similar findings. HPL-treated groups showed more Ki-67-positive cells compared to the PFAT- and corticosteroid-treated groups. CONCLUSIONS: HPL treatment effectively reduced inflammation, promoted the recovery of corneal thickness, and induced cellular proliferation after dehydration, demonstrating its potential as a treatment for EK.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Tsai CY, Huang WL, Yang SC, et al. Human Platelet Lysate Treatment for Exposure Keratopathy: An In Vivo Confocal Microscopy and Anterior Segment OCT Study. Invest Ophthalmol Vis Sci. 2025. PMID: 40552916. doi:10.1167/iovs.66.6.73

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。